

CLAIMS

- the method of claim 1 where
- the method of claim 2 where

(d) comparing the amount of polypeptide detected in steps (b) and (c) to

5. A monoclonal antibody that binds to a polypeptide comprising an

6. A method for inhibiting the development of prostate cancer in a

7 The method of claim 6 wherein the monoclonal antibody is conjugated

8. A method for detecting prostate cancer in a patient comprising:

(a) obtaining a biological sample from the patient;

(b) contacting the sample with at least two oligonucleotide primers in a

(c) detecting in the sample a DNA sequence that amplifies in the presence

9 The method of claim 8, wherein at least one of the oligonucleotides

sequence selected from SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224.

10. A diagnostic kit comprising:

- (a) one or more monoclonal antibodies of claim 5; and
- (b) a detection reagent.

11. A diagnostic kit comprising:

(a) one or more monoclonal antibodies that bind to a polypeptide encoded by a DNA molecule having a nucleotide sequence selected from the group consisting of SEQ ID Nos: 5-7, 30-40, 46, 53, 66-69, 71, 72, 75-78, 80, 82-86, 88, 89, 91, 94-96, 98-102, 105, 106, 161-170, 179, 180, 182-187, 189, 190, 192, 195-197, 199-202, 205, 206, the complements of said sequences and variants of said nucleotide sequences; and

- (b) a detection reagent.

12. The kit of claims 10 or 11 wherein the monoclonal antibodies are immobilized on a solid support.

13. The kit of claim 12 wherein the solid support comprises nitrocellulose, latex or a plastic material.

14. The kit of claims 10 or 11 wherein the detection reagent comprises a reporter group conjugated to a binding agent.

15. The kit of claim 14 wherein the binding agent is selected from the group consisting of anti-immunoglobulins, Protein G, Protein A and lectins.

16. The kit of claim 14 wherein the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.

17. A diagnostic kit comprising at least two oligonucleotide primers, at least one of the oligonucleotide primers being specific for a DNA molecule encoding a

09030606.022598

ic portion of a
d sequence enc
isting of nucleoti
177 and 179-22
e sequences.

f claim 17 where
ontiguous nucle
-3, 5-107, 109-
ecting prostate c
gical sample from
ological sample v
ypeptide compr
d protein compr
ce selected from
5-107, 109-111
uences and varia
sample a DN
g prostate cancer

claim 19 wherein
s of a DNA mol
2-3, 5-107, 109-
t comprising an
de comprising a
ein comprising a
cted from the gr

224.

19.
(a)

(a)

(b)

olypeptide co-
id protein co-
nce selected
5-107, 109-
quences and v

(c)

20.

21

22. The diagnostic kit of claim 21 wherein the oligonucleotide probe comprises at least about 15 contiguous nucleotides of a DNA molecule having a sequence selected from the group consisting of SEQ ID Nos: 2-3, 5-107, 109-111, 115-171, 173-175, 177 and 179-224.